117 related articles for article (PubMed ID: 23755925)
1. Discordance of KRAS mutational status in a single colonic resection specimen in a patient with colorectal cancer: a case report and review of the literature.
Smaglo BG; Marshall JL
Clin Colorectal Cancer; 2013 Sep; 12(3):214-7. PubMed ID: 23755925
[No Abstract] [Full Text] [Related]
2. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
3. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
4. A novel K-ras mutation in colorectal cancer. A case report and literature review.
Palmirotta R; Savonarola A; Formica V; Ludovici G; Del Monte G; Roselli M; Guadagni F
Anticancer Res; 2009 Aug; 29(8):3369-74. PubMed ID: 19661358
[TBL] [Abstract][Full Text] [Related]
5. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
7. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
8. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
9. [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].
Pu XX; Deng YH; Xu F; Xiao J; Guo HQ; Huang H; Tian Y; He YJ; Lin TY
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov; 12(6):594-7. PubMed ID: 19921572
[TBL] [Abstract][Full Text] [Related]
10. Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Chang SC; Denne J; Zhao L; Horak C; Green G; Khambata-Ford S; Bray C; Celik I; Van Cutsem E; Harbison C
Clin Colorectal Cancer; 2013 Sep; 12(3):195-203.e2. PubMed ID: 23978462
[TBL] [Abstract][Full Text] [Related]
11. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
13. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Tougeron D; Cortes U; Ferru A; Villalva C; Silvain C; Tourani JM; Levillain P; Karayan-Tapon L
Cancer Chemother Pharmacol; 2013 Aug; 72(2):397-403. PubMed ID: 23765179
[TBL] [Abstract][Full Text] [Related]
16. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
[TBL] [Abstract][Full Text] [Related]
17. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
[TBL] [Abstract][Full Text] [Related]
20. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]